A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2016
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ELUXA 1
- Sponsors Hanmi Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 09 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 09 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2018.